Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03665129 · ClinicalTrials.gov registry record · Phase 1
IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Innate Pharma.
- Terminated
- Registry status
- Phase 1
- Development phase
- 73
- Enrollment target
NCT03665129: Clinical Trial Phase 1 study, sponsored by Innate Pharma.
NCT03665129 is a Phase 1 study that was terminated before completion, run by Innate Pharma. The registered enrollment target is 73 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (22% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03665129, a Phase 1 study, was terminated before completion, sponsored by Innate Pharma.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 73 participants
- Enrollment target
Study Summary
This is a multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, antitumor activity of IPH5401 (anti C5aR) in combination with Durvalumab (MEDI4736) in Adult Subjects with selected advanced solid tumors.
Primary Outcome
To assess the occurrence of Drug Limited Toxicities (DLTs)
Interventions
- BIOLOGICAL IPH5401 and Durvalumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2018-09-07 |
| Est. Completion | 2021-02-24 |
| Phase | Phase 1 |
Why NCT03665129 stopped before completion
NCT03665129 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 73 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (22% higher).
The record links to 0 conditions, and to 1 intervention - of which IPH5401 and Durvalumab is the first listed.
NCT03665129 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03665129 about?
NCT03665129 is a clinical study titled "IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors". This is a multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, antitumor activity of IPH5401 (anti C5aR) in combination with Durvalumab (MEDI4736) in Adult Subjects with selected advanced solid tumors.
What is the current status of trial NCT03665129?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 73 participants. The study started on 2018-09-07. Estimated completion is 2021-02-24.
What interventions are being tested in trial NCT03665129?
The interventions under investigation include: IPH5401 and Durvalumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03665129?
This trial is sponsored by Innate Pharma, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03665129's enrollment target sits among peer trials
73 732nd of 2000 higher than 1,265 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03661307 · 73 participants · Phase 1
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
- NCT05386108 · 73 participants · Phase 1
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- NCT05961592 · 73 participants · Phase 1
R-2487 in Patients With Rheumatoid Arthritis
- NCT06150664 · 73 participants · Phase 1
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI